ABL1 and acute lymphoblastic leukemia: These data demonstrate different mechanisms of action for ABT-737 and imatinib in BCR-ABL-positive ALL cells and suggest a role for miR-17∼92 encoded miRNAs in BCL2-mediated apoptotic pathways in these cells.